These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7838889)

  • 1. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies.
    Saletu B; Schulz H; Herrmann WM; Anderer P; Shrotriya RC; Vanbrabant E
    Pharmacopsychiatry; 1994 Sep; 27(5):189-97. PubMed ID: 7838889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia.
    Saletu B; Grünberger J; Anderer P; Linzmayer L
    Methods Find Exp Clin Pharmacol; 1996; 18(1):67-81. PubMed ID: 8721258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration.
    Saletu B; Grünberger J; Anderer P; Linzmayer L; König P
    Arzneimittelforschung; 1995 Mar; 45(3):217-29. PubMed ID: 7741773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies.
    Saletu B; Grünberger J; Anderer R
    Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):510-24. PubMed ID: 2086492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry.
    Saletu B; Grünberger J; Linzmayer L; Anderer P
    Psychopharmacology (Berl); 1992; 109(1-2):30-40. PubMed ID: 1365669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hypoxia model in human psychopharmacology: neurophysiological and psychometric studies with aniracetam i.v.
    Saletu B; Grünberger J
    Hum Neurobiol; 1984; 3(3):171-81. PubMed ID: 6434496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia.
    Saletu B; Grünberger J; Anderer P; Linzmayer L
    Methods Find Exp Clin Pharmacol; 1996; 18(1):55-66. PubMed ID: 8721257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man.
    Saletu B; Hitzenberger G; Grünberger J; Anderer P; Zyhlarz G; Linzmayer L; Rameis H
    Int J Clin Pharmacol Ther; 1995 May; 33(5):249-62. PubMed ID: 7655763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry.
    Saletu B; Grünberger J; Linzmayer L; Anderer P
    J Neural Transm Park Dis Dement Sect; 1990; 2(4):305-25. PubMed ID: 2127674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutamatergic drug: double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia.
    Saletu B; Grünberger J; Anderer P; Linzmayer L; König P
    Br J Clin Pharmacol; 1996 Feb; 41(2):89-99. PubMed ID: 8838434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical-pharmacological study with the two isomers (d-, l-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: blood levels, EEG mapping and safety evaluation.
    Saletu B; Barbanoj MJ; Anderer P; Sieghart W; Grünberger J
    Methods Find Exp Clin Pharmacol; 1993 Jun; 15(5):291-312. PubMed ID: 8412414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encephalotropic and psychotropic effects of intravenous buflomedil in the elderly: double-blind, placebo-controlled pharmaco-EEG and psychometric studies.
    Saletu B; Grünberger J; Linzmayer L; Stöhr H
    Int J Clin Pharmacol Res; 1984; 4(2):95-107. PubMed ID: 6469443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative EEG and psychometric analyses in assessing CNS-activity of Ro 13-5057--a cerebral insufficiency improver.
    Saletu B; Grünberger J; Linzmayer L
    Methods Find Exp Clin Pharmacol; 1980 Oct; 2(5):269-85. PubMed ID: 6927816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry.
    Arnold O; Saletu B; Anderer P; Assandri A; di Padova C; Corrado M; Saletu-Zyhlarz GM
    Eur Neuropsychopharmacol; 2005 Oct; 15(5):533-43. PubMed ID: 16046102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.
    Saletu B; Grünberger J; Linzmayer L; Anderer P
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):12-27. PubMed ID: 2883677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: pharmaco-EEG and psychometric studies.
    Saletu B; Grünberger J; Linzmayer L
    Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):51-65. PubMed ID: 2921096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers].
    Nobuhara K
    Seishin Shinkeigaku Zasshi; 1993; 95(5):392-416. PubMed ID: 8356168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography).
    Saletu B; Anderer P; Wolzt M; Nosiska D; Assandri A; Noseda E; Nannipieri F; Saletu-Zyhlarz GM
    Neuropsychobiology; 2009; 59(2):110-22. PubMed ID: 19365151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clinical pharmacological trials with a novel partial benzodiazepine agonist/antagonist Ro 17-1812 using pharmaco-EEG and psychometry.
    Saletu B; Grünberger J; Linzmayer L
    Methods Find Exp Clin Pharmacol; 1986 Jun; 8(6):373-89. PubMed ID: 3736281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Functional improvement of the aging brain: placebo controlled pharmaco-EEG and psychometric studies with a metabolically active hemoderivative (Actovegin)].
    Saletu B; Grünberger J; Linzmayer L; Stöhr H
    Z Gerontol; 1984; 17(5):271-9. PubMed ID: 6395527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.